Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial

Uzma N Sarwar, Pamela Costner, Mary E Enama, Nina Berkowitz, Zonghui Hu, Cynthia S Hendel, Sandra Sitar, Sarah Plummer, Sabue Mulangu, Robert T Bailer, Richard A Koup, John R Mascola, Gary J Nabel, Nancy J Sullivan, Barney S Graham, Julie E Ledgerwood, VRC 206 Study Team, Ingelise Gordon, Lasonji Holman, Floreliz Mendoza, Laura Novik, Jamie Saunders, Kathy Zephir, Niraj Desai, Sheryl Young, Joseph Casazza, Brenda Larkin, Galina Yamshchikov, Olga Vasilenko, Phillip L Gomez, Charla Andrews, Michelle Conan-Cibotti, Kimberly Wallace, Judy Stein, Rebecca Sheets, Hope Decederfelt, Judith Starling, Phyllis Renehan, Uzma N Sarwar, Pamela Costner, Mary E Enama, Nina Berkowitz, Zonghui Hu, Cynthia S Hendel, Sandra Sitar, Sarah Plummer, Sabue Mulangu, Robert T Bailer, Richard A Koup, John R Mascola, Gary J Nabel, Nancy J Sullivan, Barney S Graham, Julie E Ledgerwood, VRC 206 Study Team, Ingelise Gordon, Lasonji Holman, Floreliz Mendoza, Laura Novik, Jamie Saunders, Kathy Zephir, Niraj Desai, Sheryl Young, Joseph Casazza, Brenda Larkin, Galina Yamshchikov, Olga Vasilenko, Phillip L Gomez, Charla Andrews, Michelle Conan-Cibotti, Kimberly Wallace, Judy Stein, Rebecca Sheets, Hope Decederfelt, Judith Starling, Phyllis Renehan

Abstract

Background: Ebolavirus and Marburgvirus cause severe hemorrhagic fever with high mortality and are potential bioterrorism agents. There are no available vaccines or therapeutic agents. Previous clinical trials evaluated transmembrane-deleted and point-mutation Ebolavirus glycoproteins (GPs) in candidate vaccines. Constructs evaluated in this trial encode wild-type (WT) GP from Ebolavirus Zaire and Sudan species and the Marburgvirus Angola strain expressed in a DNA vaccine.

Methods: The VRC 206 study evaluated the safety and immunogenicity of these DNA vaccines (4 mg administered intramuscularly by Biojector) at weeks 0, 4, and 8, with a homologous boost at or after week 32. Safety evaluations included solicited reactogenicity and coagulation parameters. Primary immune assessment was done by means of GP-specific enzyme-linked immunosorbent assay.

Results: The vaccines were well tolerated, with no serious adverse events; 80% of subjects had positive enzyme-linked immunosorbent assay results (≥30) at week 12. The fourth DNA vaccination boosted the immune responses.

Conclusions: The investigational Ebolavirus and Marburgvirus WT GP DNA vaccines were safe, well tolerated, and immunogenic in this phase I study. These results will further inform filovirus vaccine research toward a goal of inducing protective immunity by using WT GP antigens in candidate vaccine regimens.

Clinical trials registration: NCT00605514.

Keywords: DNA; ebola; ebolavirus; filovirus; marburg; marburgvirus; vaccine.

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Figures

Figure 1.
Figure 1.
Schematic diagram of study design, vaccination schedule and follow-up showing screening, enrollment, and follow-up. The original protocol design included 3 study vaccinations at day 0 and weeks 4 and 8, with 32 weeks of follow-up. An optional fourth vaccination was added by amendment with 12 weeks of additional follow-up. Abbreviation: WT, wild-type.
Figure 2.
Figure 2.
Glycoprotein (GP)-specific mean antibody responses assessed by enzyme-linked immunosorbent assay (ELISA) for GP (AN), GP (S), and GP (Z). Mean titers with upper 95% confidence intervals are shown for 3 time points: 4 and 24 weeks after the third vaccination and 4 weeks after the fourth DNA vaccination. The threshold for positivity in this assay was a reciprocal dilution of 30 and is indicated by a dashed line.
Figure 3.
Figure 3.
Ebolavirus and Marburgvirus neutralization as the percentage of infection in the presence of subject serum samples relative to control infection. Neutralization is represented as the percentage of infection in the presence of subject serum samples relative to control infection in the absence of serum samples. Results are shown for 9 of 10 EBO vaccinees (A) and 9 of 10 MAR vaccinees (B) at 3 time points: at baseline (preimmune) and after the third and fourth DNA vaccinations.
Figure 4.
Figure 4.
Frequency of CD4+ and CD8+ T-cell responses by intracellular cytokine staining and enzyme-linked immunospot assay (ELISPOT) analysis. The percentage of responders is shown for each vaccine antigen at 4 time points for CD4+ and CD8+ intracellular cytokine staining and ELISPOT.

References

    1. Sanchez A, Kiley MP, Klenk HD, Feldmann H. Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. J Gen Virol. 1992;73((pt 2)):347–57.
    1. Hart MK. Vaccine research efforts for filoviruses. Int J Parasitol. 2003;33:583–95.
    1. Dessen A, Volchkov V, Dolnik O, Klenk HD, Weissenhorn W. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J. 2000;19:4228–36.
    1. Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease): Outbreaks. Known cases and outbreaks of Ebola hemorrhagic fever, in chronological order. Available at: . Accessed 12 August 2014.
    1. Sarwar UN, Sitar S, Ledgerwood JE. Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine. Travel Med Infect Dis. 2011;9:126–34.
    1. Centers for Disease Control and Prevention. 2014 Ebola outbreak in West Africa. . Accessed 12 August 2014.
    1. Centers for Disease Control and Prevention. Marburg hemorrhagic fever (Marburg HF) . Accessed 12 August 2014.
    1. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–90.
    1. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol. 2006;80:9659–66.
    1. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet. 2006;367:1399–404.
    1. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–9.
    1. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267–77.
    1. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304–13.
    1. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006;3:e177.
    1. Division of AIDS Table for Grading the Severity of Adverse Events (December 2004) Available at: .
    1. Yang ZY, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004;78:5642–50.
    1. Barouch DH, Yang ZY, Kong WP, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol. 2005;79:8828–34.
    1. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007;25:4085–92.
    1. Ledgerwood JE, Hu Z, Gordon IJ, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol. 2012;19:1792–7.
    1. Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203:1396–404.
    1. Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine. 2008;26:6338–43.
    1. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis. 2006;194:1650–60.
    1. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis. 2007;196:1732–40.
    1. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011;11:916–24.
    1. Fausther-Bovendo H, Mulangu S, Sullivan NJ. Ebolavirus vaccines for humans and apes. Curr Opin Virol 2012; 2:324–9.
    1. Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011; 17:1128–31.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever